Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice ... Right now my own tech stock allocation is full.

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...

GSK will pay $80 million upfront and as much as $570 million to gain full development and commercialization rights to ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it ...

Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of ...